Vitrectomy using precise fluid movement

Article

Breaking news from the floor of ESCRS

With fluidics in modern vitrectomy one of the continuing hot topics in ophthalmology Oertli's focus at this year's ESCRS was its Faros fluidics system which, using the peristaltic principle allows doctors to exercise precision regulation. The compact device allows immediate vacuum build-up, which can be precisely controlled using the system's foot pedal. The pump also enables control of aspiration flow and can control micro-flow rates in the range of 1 mL so that there are no effects as a result of peristaltic rolls. Additionally, the system includes the easyPhaco technology for 2.2 and 1.6 mm micro incision surgery.

Peristaltic pumps work with flow by means of roller systems. Compression of the tubes by the rotating movement 'milks' the liquid column out of the tubing system. While this is happening the flow can be directly controlled. The preset vacuum is achieved as soon as the outflow is occluded, i.e. As a rule, at the tip of the cutter. As soon as occlusion occurs, the vacuum starts building up, the rollers begin to move more slowly and the outflow decreases. How quickly the rollers respond can partly be influenced by how this parameter is present.

Oertli has recently undertaken a great deal of research looking at two pump concepts, flow controlled and vacuum controlled, or peristaltic and venture. Visit www.oertl-instruments.com for more information.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.